The Alleviate Effects of Naringenin on High-Fat and High-Fructose Diet Fed Non-alcoholic Fatty Liver Disease Mice

被引：0
|
作者：
Ge J. [1 ,2 ]
Ruan Z. [1 ,2 ]
机构：
[1] College of Food Science, Nanchang University, Nanchang
[2] State Key Laboratory of Food Science and Technology, Nanchang University, Nanchang
来源：
Journal of Chinese Institute of Food Science and Technology | 2023年 / 23卷 / 09期
关键词：
intestinal permeability; lipopolysaccharides (LPS); naringenin; non-alcoholic fatty liver disease (NAFLD);
D O I：
10.16429/j.1009-7848.2023.09.007
中图分类号：
学科分类号：
摘要：
Objective: To investigate the protective effects and mechanism of naringenin (NAR) on high-fat, high-sugar induced mice with non-alcoholic fatty liver disease (NAFLD). Methods: Mice were fed with a high-fat and high-fructose diet to establish a NAFLD model, orally administration of naringenin was performed during the experiment. After 9 weeks, the body weight, epididymis fat weight and liver weight were observed, levels of the serum and liver triglyceride, serum ALT, AST were measured; Levels of hepatic inflammatory factors and serum lipopolysaccharides (LPS) was determined by ELISA, the pathological changes of liver tissues in mice were observed, and the localization of bacteria derived lipopolysaccharides in the liver flora was determined using anti- LPS obtained from Escherichia coli. Results: Naringenin significantly reduced the increased body mass (P＜0.001) and liver weight of NAFLD mice (P＜0.01) induced by HFFD, decrease the serum and hepatic TG level (P＜0.05), the serum ALT (P ＜0.05) and AST levels (P＜0.01), and improved the liver steatosis and lipid accumulation. Meanwhile, naringenin reduce the localization of bacteria derived LPS (P＜0.01) in mice liver and intestinal permeability. Conclusion: This study initially reveals that naringenin may reduce the bacteria-derived LPS location in mice liver by reducing intestinal permeability, thereby reducing liver inflammation, and alleviating the high-fat and high-fructose induced non-alcoholic fatty liver diseases in mice. © 2023 Chinese Institute of Food Science and Technology. All rights reserved.
引用
收藏
页码：60 / 66
页数：6
相关论文
共 23 条
  • [1] WANG R, MONIRUZZAMAN M, WONG K Y, Et al., Gut microbiota shape the inflammatory response in mice with an epithelial defect, Gut Microbes, 13, 1, pp. 1-18, (2021)
  • [2] LIM G E H, TANG A, NG C H, Et al., An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD, Clin Gastroenterol Hepatol, 21, 3, pp. 619-629, (2023)
  • [3] LIANG Y, CHEN H, LIU Y, Et al., Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease: A 4.6-year cohort study in China, J Clin Endocrinol Metab, 107, 1, pp. 88-97, (2022)
  • [4] KESSOKU T, KOBAYASHI T, TANAKA K, Et al., The role of leaky gut in nonalcoholic fatty liver disease: A novel therapeutic target, International Journal of Molecular Sciences, 22, (2021)
  • [5] COMPARE D, COCCOLI P, ROCCO A, Et al., Gut-liver axis: The impact of gut microbiota on non alcoholic fatty liver disease, Nutrition, Metabolism and Cardiovascular Diseases, 22, 6, pp. 471-476, (2012)
  • [6] CARPINO G, DEL BEN M, PASTORI D, Et al., Increased liver localization of lipopolysaccharides in human and experimental NAFLD, Hepatology, 72, 2, pp. 470-485, (2020)
  • [7] CHIECHIO S, ZAMMATARO M, BARRESI M, Et al., A Standardized extract prepared from red orange and lemon wastes blocks high-fat diet-induced hyperglycemia and hyperlipidemia in mice, Molecules, 26, 14, (2021)
  • [8] TANG X F, ZHONG M J, SHEN H J., Effect of naringenin Liposomes on lipid metabolism in nonalcoholic fatty liver disease rats, Journal of Practical Hepatology, 23, 3, pp. 328-331, (2020)
  • [9] CHIECHIO S, ZAMMATARO M, BARRESI M, Et al., A standardized extract prepared from red orange and lemon wastes blocks high-fat diet-induced hyperglycemia and hyperlipidemia in mice, Molecules, 26, 14, (2021)
  • [10] YANG Y, WU Y, ZOU J, Et al., Naringenin attenuates non-alcoholic fatty liver disease by enhancing energy expenditure and regulating autophagy via AMPK, Front Pharmacol, 12, pp. 1806-1821, (2021)
123